Obimet GX 1 Tablet PR is a combination oral antihyperglycemic agent containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The combination of these two agents provides complementary mechanisms of action, effectively reducing fasting and postprandial blood glucose levels. Obimet GX 1 Tablet PR is recommended as an adjunct to diet and exercise to achieve optimal glycemic control in patients inadequately controlled by either agent alone. It is particularly useful in patients with insulin resistance and impaired beta-cell function. The extended-release formulation allows for once-daily dosing, improving patient compliance. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose, renal function, and lactic acid levels is essential to minimize the risk of adverse effects, including hypoglycemia and lactic acidosis. This medication should be prescribed under medical supervision with appropriate lifestyle modifications for effective diabetes management.